Literature DB >> 3936350

AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission.

V Gualandri, G Franceschini, C R Sirtori, G Gianfranceschi, G B Orsini, A Cerrone, A Menotti.   

Abstract

The AIMilano apoprotein variant is associated with a marked reduction of high density lipoprotein (HDL) cholesterol levels and with increased triglyceridemia. In spite of the low HDL-cholesterol (HDL-Ch), carriers do not generally show clinical signs of atherosclerosis. The biochemical disorder is linked to a molecular change in apoprotein AI, that is, an arg----cys substitution in the 173 position, thus allowing the formation of AIMilano-AIMilano dimers and AIMilano-AII complexes. The origin of the variant gene has been located in Limone sul Garda, a small community in Northern Italy (about 1,000 individuals). This community has a genetic, biochemical, and clinical individuality, consequent to its isolation up to a few years ago; the citizens show highly uniform alimentary habits and elevated consanguinity. The complete population of the small village was sampled, and, by the use of an analytical isoelectric focusing technique for the detection of the mutant, a total of 33 living carriers, ranging in age from 2 to 81 yrs, were identified. Analysis of the genealogic tree of the complete family groups showed that the apoprotein (apo) AIMilano is transmitted as an autosomal dominant trait, all carriers coming from a single mating couple, living in the eighteenth century. The carriers are heterozygous for the apoprotein variant.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3936350      PMCID: PMC1684746     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  15 in total

1.  The electrocardiogram in population studies. A classification system.

Authors:  H BLACKBURN; A KEYS; E SIMONSON; P RAUTAHARJU; S PUNSAR
Journal:  Circulation       Date:  1960-06       Impact factor: 29.690

2.  Characterization of high density lipoproteins in patients heterozygous for Tangier disease.

Authors:  G Assmann; O Simantke; H E Schaefer; E Smootz
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

3.  Carbohydrate diet-induced changes in very low density lipoprotein composition and structure.

Authors:  J L Witztum; G Schonfeld
Journal:  Diabetes       Date:  1978-12       Impact factor: 9.461

4.  [Precipitation of alpha and beta serum lipoproteins by sulfate polysaccharides in the presence of manganese chloride].

Authors:  M Burstein; R Morfin
Journal:  Nouv Rev Fr Hematol       Date:  1969 Mar-Apr

5.  [Enzymatic determination of total cholesterol in serum (author's transl)].

Authors:  P Röschlau; E Bernt; W Gruber
Journal:  Z Klin Chem Klin Biochem       Date:  1974-09

6.  Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease).

Authors:  E J Schaefer; L A Zech; D E Schwartz; H B Brewer
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

7.  A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family.

Authors:  G Franceschini; C R Sirtori; A Capurso; K H Weisgraber; R W Mahley
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

8.  Relation between the HDL apoproteins and AI isoproteins in subjects with the AIMilano abnormality.

Authors:  G Franceschini; M Sirtori; G Gianfranceschi; C R Sirtori
Journal:  Metabolism       Date:  1981-05       Impact factor: 8.694

9.  Fish eye disease: a new familial condition with massive corneal opacities and dyslipoproteinaemia.

Authors:  L A Carlson
Journal:  Eur J Clin Invest       Date:  1982-02       Impact factor: 4.686

10.  A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins.

Authors:  K H Weisgraber; T P Bersot; R W Mahley; G Franceschini; C R Sirtori
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

View more
  24 in total

1.  Towns with extremely low mortality due to ischemic heart disease in Spain.

Authors:  María José Medrano; Raquel Boix; Alba Palmera; Rebeca Ramis; Iñaki Galán; Gonzalo López-Abente
Journal:  BMC Public Health       Date:  2012-03-09       Impact factor: 3.295

Review 2.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 3.  Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary.

Authors:  Dhruv Kazi; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

4.  Symptomatic vs. asymptomatic plaque classification in carotid ultrasound.

Authors:  Rajendra U Acharya; Oliver Faust; A P C Alvin; S Vinitha Sree; Filippo Molinari; Luca Saba; Andrew Nicolaides; Jasjit S Suri
Journal:  J Med Syst       Date:  2011-01-18       Impact factor: 4.460

Review 5.  Genetic control of apoprotein A-I and atheroprotection: some insights from inbred strains of mice.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

Review 6.  Recombinant high-density lipoprotein formulations.

Authors:  Esad Vucic; Robert S Rosenson
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

Review 7.  Regression of atherosclerosis.

Authors:  Benoit J Arsenault; Ekaterini A Kritikou; Jean-Claude Tardif
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

8.  Apolipoprotein A-I variants. Naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I.

Authors:  A von Eckardstein; H Funke; A Henke; K Altland; A Benninghoven; G Assmann
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

9.  Successful treatment of established heart failure in mice with recombinant HDL (Milano).

Authors:  Joseph Pierre Aboumsallem; Mudit Mishra; Ruhul Amin; Ilayaraja Muthuramu; Herman Kempen; Bart De Geest
Journal:  Br J Pharmacol       Date:  2018-09-19       Impact factor: 8.739

10.  In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia.

Authors:  P Roma; R E Gregg; M S Meng; R Ronan; L A Zech; G Franceschini; C R Sirtori; H B Brewer
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.